However, when combined with insulin or sulfonylureas, the risk of hypoglycemia increases substantially, potentially affecting twenty to thirty percent of patients if doses of concurrent medications are not appropriately adjusted
The implications of this lawsuit may be profound, potentially leading to more stringent regulations on GLP-1 agonists and affecting their availability and public trust in the future
Semaglutide is a glucagon-like peptide-1 receptor agonist [that] has been extensively studied across a broad spectrum of cardiometabolic diseases, Philip N
The company's lead asset, bimagrumab, is being advanced in a Phase 2b study as a novel treatment for obesity to help adults achieve and maintain both substantial fat loss and a healthy body composition, with additional indications to follow
Stay monitored
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study